No Data
No Data
Express News | Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target
Cartesian Therapeutics Analyst Ratings
Promising Potential of Cartesian Therapeutics' Descartes-08 in GMG Treatment: A Buy Recommendation
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40
Mizuho Securities Sticks to Its Buy Rating for Cartesian Therapeutics (RNAC)
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients